The state of Kentucky currently has 5 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Louisville, Lexington, Owensboro and Paducah.
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Recruiting
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Ear... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: University of Louisville, Louisville, Kentucky +1 locations
Conditions: Multiple Sclerosis, Relapsing-Remitting
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
02/18/2024
Locations: Uni of Louisville Clncl Trials Unit Novak Center, Louisville, Kentucky
Conditions: Multiple Sclerosis (MS)
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Recruiting
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relations... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/16/2024
Locations: University of Kentucky Site Number : 8400106, Lexington, Kentucky
Conditions: Primary Progressive Multiple Sclerosis
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Recruiting
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
12/22/2023
Locations: Baptist Health Lexington, Nicholasville, Kentucky
Conditions: Multiple Sclerosis, Relapsing-Remitting
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
Recruiting
The investigators' overall hypothesis is that appearance or worsening of relapsing-remitting multiple sclerosis (RR-MS) symptoms are affected by various factors including stress, hormonal cycles, illness and missed medications.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
09/21/2023
Locations: University of Louisville (recruiting nationwide), Louisville, Kentucky
Conditions: Relapsing Remitting Multiple Sclerosis